- Home
- CRDF vs GLSI Comparison
CRDF vs GLSI Comparison
Compare CRDF & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- GLSI
- Stock Information
- Founded
- CRDF 1999
- GLSI 2006
- Country
- CRDF United States
- GLSI United States
- Employees
- CRDF N/A
- GLSI N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- CRDF Health Care
- GLSI Health Care
- Exchange
- CRDF Nasdaq
- GLSI Nasdaq
- Market Cap
- CRDF 144.4M
- GLSI 149.5M
- IPO Year
- CRDF N/A
- GLSI 2020
- Fundamental
- Price
- CRDF $2.00
- GLSI $11.44
- Analyst Decision
- CRDF Strong Buy
- GLSI Strong Buy
- Analyst Count
- CRDF 5
- GLSI 1
- Target Price
- CRDF $11.10
- GLSI $39.00
- AVG Volume (30 Days)
- CRDF 1.1M
- GLSI 57.0K
- Earning Date
- CRDF 11-06-2025
- GLSI 11-13-2025
- Dividend Yield
- CRDF N/A
- GLSI N/A
- EPS Growth
- CRDF N/A
- GLSI N/A
- EPS
- CRDF N/A
- GLSI N/A
- Revenue
- CRDF $545,000.00
- GLSI N/A
- Revenue This Year
- CRDF N/A
- GLSI N/A
- Revenue Next Year
- CRDF N/A
- GLSI N/A
- P/E Ratio
- CRDF N/A
- GLSI N/A
- Revenue Growth
- CRDF N/A
- GLSI N/A
- 52 Week Low
- CRDF $1.90
- GLSI $8.06
- 52 Week High
- CRDF $5.64
- GLSI $15.50
- Technical
- Relative Strength Index (RSI)
- CRDF 48.21
- GLSI 51.67
- Support Level
- CRDF N/A
- GLSI N/A
- Resistance Level
- CRDF $2.27
- GLSI $13.00
- Average True Range (ATR)
- CRDF 0.11
- GLSI 0.62
- MACD
- CRDF -0.04
- GLSI -0.44
- Stochastic Oscillator
- CRDF 87.89
- GLSI 88.00
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.